VolitionRx Ltd. (NYSE American: VNRX) on Tuesday provided a corporate update detailing recent clinical and commercial advancements across its diagnostics portfolio. The company highlighted the submission of a feline lymphoma manuscript tied to a potential $5 million milestone payment, alongside continued momentum in licensing discussions with more than a dozen global diagnostic and liquid biopsy companies.
The update also noted validation progress for Volition's Capture-Seq cancer detection platform, expansion of its sepsis-focused Nu.Q NETs program, and ongoing efforts to secure reimbursement in France for its lung cancer assay ahead of anticipated routine clinical use. These developments underscore the company's commitment to advancing its pipeline of simple, cost-effective blood tests for early detection and monitoring of diseases.
Volition's technology focuses on epigenetics, aiming to detect and monitor various diseases including cancers and sepsis. The company believes earlier detection can prolong life and improve quality of life for patients. The potential $5 million milestone payment from the feline lymphoma manuscript represents a significant financial incentive tied to research progress.
Licensing discussions with over a dozen global diagnostic and liquid biopsy companies indicate growing interest in Volition's technology platform. The Capture-Seq platform's validation progress suggests it may soon be ready for broader application. Meanwhile, the Nu.Q NETs program expansion targets sepsis, a critical area where early detection can save lives.
In France, Volition is working to secure reimbursement for its lung cancer assay, a crucial step toward routine clinical use. Reimbursement would allow healthcare providers to adopt the test more widely, potentially improving lung cancer detection rates. Lung cancer remains one of the leading causes of cancer deaths worldwide, and earlier detection can significantly improve outcomes.
Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. The company is dedicated to saving lives and improving outcomes for both humans and animals through earlier disease detection and monitoring.
The full press release detailing these updates can be accessed at https://ibn.fm/nX9FK. For more information about Volition and its pipeline, visit https://volition.com/.
